Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

North Central Cancer Treatment Group — finding ways to make treatment easier

28.02.2006


Mayo Clinic researchers working in concert with other North Central Cancer Treatment Group (NCCTG) investigators have found that administering epoetin alfa for anemia once every three weeks to patients with anemia and cancer, instead of the traditional weekly epoetin treatments, maintains similar levels of red blood cells. Results of the study are available online in the Journal of Clinical Oncology.



Anemia is a common complication of cancer and can significantly impair a patient’s quality of life, causing tiredness, shortness of breath, dizziness and other problems. Epoetin alfa stimulates bone marrow production of blood cells, thereby reducing anemia. "We are constantly looking for ways to make treatments easier for patients," says David Steensma, M.D., Mayo Clinic oncologist and lead author of the study. "Sometimes this means finding ways to treat side effects. In this case we studied how to treat a side effect without sacrificing as much of the patient’s time and money."

Dr. Steensma and his team studied 360 patients who were randomly assigned to receive either the standard protocol of 40,000 units (40K) of epoetin alfa once a week for 21 weeks, or 40K units of epoetin alfa once a week for three weeks followed by 120,000 units (120K) of epoetin alfa once every three weeks for the remaining 18 weeks. The investigators found no statistical difference in the proportion of patients requiring transfusions due to low hemoglobin between the groups. Side effects, including thromboembolism (blood clot in a blood vessel) and overall survival also were similar. Hemoglobin levels were slightly greater throughout the study for the patients enrolled in the 40K group, but those receiving 120K every three weeks still maintained a level that did not require transfusions. At the end of the study, patients in each group reported a similar quality of life.


While they find the results of this study promising, Dr. Steensma and his team say that a larger study must be done to more definitively show equivalence between the two therapies. Although this reduced frequency dosing schedule would be more convenient for patients, the researchers say that clinicians will have to decide whether the potentially lower hemoglobin levels are an acceptable trade-off.

John Murphy | EurekAlert!
Further information:
http://www.mayo.edu
http://ncctg.mayo.edu
http://cancercenter.mayo.edu

More articles from Health and Medicine:

nachricht Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University

nachricht The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

Im Focus: Fraunhofer ISE Develops Highly Compact, High Frequency DC/DC Converter for Aviation

The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.

Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

UTSA study describes new minimally invasive device to treat cancer and other illnesses

02.12.2016 | Medical Engineering

Plasma-zapping process could yield trans fat-free soybean oil product

02.12.2016 | Agricultural and Forestry Science

What do Netflix, Google and planetary systems have in common?

02.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>